A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 9, 2026 - P1/2 | N=40 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Active, not recruiting ➔ Recruiting | N=20 ➔ 40
Enrollment change • Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3
|